Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Somatogen (SMTG) -- Ignore unavailable to you. Want to Upgrade?

To: CarlPerf who wrote (422)	2/26/1998 8:11:00 PM
From: Tim Mooney	Read Replies (1) \| Respond to of 442

I subscribe to the Medical Technology Stock Letter and bought SMTG after looking into the co (it is one of a dozen or so biotechs that the newsletter recommends and updates biweekly). Talking with the folks at MTSL earlier this week, I was told that they have contacted SMTG to tell them that they are not happy with the terms of the sale of the company. Reading between the lines of what they said (or voicing my own opinion, I'm not sure which)the point was that the price does not reflect either the value of the company or the price shareholders should receive for a reward commesurate with the risk of funding a biotech startup. This deal is pending approval of stockholders. Email them if you are not happy. SMTG's homepage to investor relations to how to contact us will get you addressed to the right person. MTSL holds out a small hope that a better offer will come from another firm.